Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 3/20 | 0.42 |
| ▸ | GABRD | O14764 | 3/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.42 |
| ▸ | GABRE | P78334 | 3/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079079 | 1.00 | HSD17B10 (0.43) | HSD17B10PKMGABRPGABRDGABRA1 | |
| SCHEMBL23927008 | 0.88 | DRD1 (0.40) | HSD17B10PKMDRD1NTRK1IGF1R | |
| SCHEMBL30079065 | 0.88 | DRD1 (0.40) | HSD17B10PKMDRD1NTRK1IGF1R | |
| SCHEMBL30079139 | 0.88 | DRD1 (0.40) | HSD17B10PKMHSD11B1DRD1NTRK1 | |
| SCHEMBL23927010 | 0.88 | DRD1 (0.40) | HSD17B10PKMHSD11B1DRD1NTRK1 | |
| SCHEMBL23927030 | 0.86 | DRD1 (0.40) | HSD17B10PKMGABRPGABRDGABRA1 | |
| SCHEMBL30079049 | 0.86 | DRD1 (0.40) | HSD17B10PKMGABRPGABRDGABRA1 | |
| SCHEMBL23926969 | 0.86 | DRD1 (0.40) | PKMDRD1NTRK1IGF1RFGFR1 | |
| SCHEMBL30079073 | 0.86 | DRD1 (0.40) | PKMDRD1NTRK1IGF1RFGFR1 | |
| SCHEMBL23926984 | 0.83 | DRD1 (0.41) | HSD17B10PKMDRD1NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | claimed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | claimed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | claimed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | claimed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | HSD17B10 2534/4885PKM 519/4885GABRP 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.